Encompass Health (NYSE:EHC – Get Free Report) issued an update on its FY 2024 earnings guidance on Thursday morning. The company provided earnings per share (EPS) guidance of 3.770-4.060 for the period, compared to the consensus estimate of 3.970. The company issued revenue guidance of $5.2 billion-$5.3 billion, compared to the consensus revenue estimate of $5.3 billion.
Encompass Health Price Performance
Shares of NYSE EHC opened at $77.69 on Thursday. The stock’s 50-day moving average is $74.10 and its two-hundred day moving average is $68.80. The company has a debt-to-equity ratio of 1.19, a current ratio of 1.28 and a quick ratio of 1.28. Encompass Health has a 1-year low of $52.32 and a 1-year high of $78.11. The company has a market cap of $7.78 billion, a price-to-earnings ratio of 22.39, a price-to-earnings-growth ratio of 1.42 and a beta of 0.93.
Encompass Health (NYSE:EHC – Get Free Report) last issued its quarterly earnings results on Wednesday, February 7th. The company reported $0.95 earnings per share for the quarter, topping the consensus estimate of $0.83 by $0.12. Encompass Health had a return on equity of 17.69% and a net margin of 7.33%. The company had revenue of $1.25 billion for the quarter, compared to the consensus estimate of $1.24 billion. Analysts forecast that Encompass Health will post 3.96 EPS for the current fiscal year.
Encompass Health Dividend Announcement
Analyst Ratings Changes
Several research analysts have recently issued reports on EHC shares. Mizuho upped their price objective on Encompass Health from $77.00 to $82.00 and gave the stock a buy rating in a research report on Friday, February 9th. Royal Bank of Canada reaffirmed an outperform rating and set a $83.00 price objective on shares of Encompass Health in a research report on Friday, February 9th. Truist Financial upped their target price on Encompass Health from $82.00 to $86.00 and gave the company a buy rating in a research report on Friday, February 9th. William Blair reissued an outperform rating on shares of Encompass Health in a research report on Wednesday, February 7th. Finally, Stephens reissued an overweight rating and issued a $85.00 target price on shares of Encompass Health in a research report on Tuesday, January 16th. Eight investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the company has an average rating of Buy and an average price target of $83.22.
Read Our Latest Stock Analysis on Encompass Health
Institutional Trading of Encompass Health
A number of hedge funds have recently added to or reduced their stakes in EHC. Worth Asset Management LLC acquired a new stake in Encompass Health during the 1st quarter worth approximately $35,000. Quarry LP purchased a new position in shares of Encompass Health during the 1st quarter worth approximately $42,000. Belpointe Asset Management LLC raised its stake in shares of Encompass Health by 88.2% during the 1st quarter. Belpointe Asset Management LLC now owns 781 shares of the company’s stock worth $42,000 after buying an additional 366 shares in the last quarter. Benjamin Edwards Inc. raised its stake in shares of Encompass Health by 89.0% during the 2nd quarter. Benjamin Edwards Inc. now owns 1,087 shares of the company’s stock worth $74,000 after buying an additional 512 shares in the last quarter. Finally, First Horizon Advisors Inc. raised its stake in shares of Encompass Health by 18.8% during the 1st quarter. First Horizon Advisors Inc. now owns 1,415 shares of the company’s stock worth $77,000 after buying an additional 224 shares in the last quarter. 97.25% of the stock is owned by institutional investors and hedge funds.
Encompass Health Company Profile
Encompass Health Corporation provides post-acute healthcare services in the United States and Puerto Rico. It owns and operates inpatient rehabilitation hospitals that provide medical, nursing, therapy, and ancillary services. The company provides specialized rehabilitative treatment on an inpatient basis to patients who have experienced physical or cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures, and various debilitating neurological conditions.
See Also
- Five stocks we like better than Encompass Health
- Investing in Commodities: What Are They? How to Invest in Them
- Delta Airline’s Put Option Activity Isn’t Bad News
- What is the FTSE 100 index?
- Krispy Kreme’s Sweet Deal: McDonald’s Partnership Sparks Growth?
- What is an Earnings Surprise?
- Bitcoin Depot Falls Into Value Territory With Expansion Underway
Receive News & Ratings for Encompass Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Encompass Health and related companies with MarketBeat.com's FREE daily email newsletter.